After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Arcutis Biotherapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Arcutis Biotherapeutics Inc is $1.08B. A total of 2.02 million shares were traded on the day, compared to an average of 5.14M shares.
In the most recent transaction, Heron Patrick J bought 21,052 shares of ARQT for 9.50 per share on Mar 04 ’24. After the transaction, the Director now owns 8,785,284 company shares. In a previous transaction on Mar 04 ’24, Watanabe Todd Franklin sold 14,903 shares at 11.12 per share. ARQT shares that the insider owns now total 874,533.
Among the insiders who sold shares, Burnett Patrick disposed of 4,782 shares on Mar 04 ’24 at a per-share price of $11.12. This resulted in the insider holding 269,300 shares of ARQT after the transaction. In another insider transaction, Matsuda Masaru sold 3,760 shares at $11.12 per share on Mar 04 ’24. Company shares held by the See Remark now total 190,424.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, ARQT has a high of $15.40 and a low of $1.76.
As of this writing, ARQT has an earnings estimate of -$0.74 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.65 per share and a lower estimate of -$0.91. The company reported an EPS of -$0.73 in the last quarter, which was 15.10% higher than expectations of -$0.86.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARQT is Buy with a score of 4.50.
